Watson announced that the FDA has approved its Abbreviated New Drug Application for Sildenafil Tablets, the generic version of Pfizer‘s Revatio.

Revatio is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Revatio is a phosphodiesterase type 5 inhibitor that increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation.

Sildenafil will be available in 20mg dosage strength tablets, and Watson intends to begin shipping the product in the near future.

For more information call (800) 382-7060 or visit www.revatio.com.